MCKESSON CORP

MCK 10-K · FY 2026
API behind this page

MCK FY 2026 request

Playground key active
Request URL /api/financials?ticker=MCK&year=2026&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2026 FY 2025 YoY
Revenue 403,430 359,051 +12.4%
Show Business Segments breakouts
Medical-Surgical Solutions · Operating Segments 11,507 11,380 +1.1%
North American Pharmaceutical · Investee 1.6 1.1 +45.5%
North American Pharmaceutical · Operating Segments 336,652 304,507 +10.6%
Oncology & Multispecialty · Operating Segments 48,423 36,862 +31.4%
Prescription Technology Solutions · Operating Segments 5,805 5,216 +11.3%
Show Consolidation Items breakouts
Material Reconciling Items 1,043 1,086 -4.0%
Cost of Revenue -388,880 -345,728 -12.5%
Gross Profit 14,550 13,323 +9.2%
Selling, General & Administrative -8,096 -8,507 +4.8%
Show Product Lines breakouts
Shipping And Handling -1.2 -1.1 -9.1%
Gain Loss Related To Litigation Settlement 3 -108 +102.8%
Restructuring Costs And Asset Impairment Charges -245 -286 +14.3%
Operating Expenses -8,338 -8,901 +6.3%
Operating Income 6,212 4,422 +40.5%
Non-Operating Income (Expense) 236 202 +16.8%
Interest Expense -247 -265 +6.8%
Show Consolidation Items breakouts
Corporate Non Segment -247 -265 +6.8%
Income Loss Including Portion Attributable To Noncontrolling Interest 6,201 4,359 +42.3%
Income Tax Expense (Benefit) -1,102 -878 -25.5%
Net Income 5,099 3,481 +46.5%
Show Equity Components breakouts
Noncontrolling Interest 197 186 +5.9%
Net Income Loss Attributable To Noncontrolling Interest -337 -186 -81.2%
Show Ownership breakouts
ClarusONE Sourcing Services, Vantage Oncology and SCRI Oncology -197 -186 -5.9%
Net Income 4,762 3,295 +44.5%
EPS (Diluted) 38.38 25.72 +49.2%
EPS (Basic) 38.55 25.86 +49.1%
Wtd Avg Shares (Diluted) 124.1 128.1 -3.1%
Wtd Avg Shares (Basic) 123.6 127.4 -3.0%
Interest Income 179 173 +3.5%
Other Non-Operating Income (Expense) 44 -38 +215.8%
Show Consolidation Items breakouts
Corporate Non Segment · Norway Disposal Group 23 — —
Operating Segments · Norway Disposal Group 503 — —
Income Before Taxes 6,201 4,359 +42.3%
Comprehensive Income 4,949 3,244 +52.6%
Income Loss From Equity Method Investments 7 9 -22.2%
Depreciation And Amortization 729 636 +14.6%
Show Business Segments breakouts
Medical-Surgical Solutions · Operating Segments 96 91 +5.5%
North American Pharmaceutical · Operating Segments 134 155 -13.5%
Oncology & Multispecialty · Operating Segments 240 148 +62.2%
Prescription Technology Solutions · Operating Segments 82 86 -4.7%
Show Consolidation Items breakouts
Corporate Non Segment 173 138 +25.4%
Material Reconciling Items 4 18 -77.8%
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax (FY) — — —
Show Derivative Risk breakouts
Foreign Exchange Forward · Designated As Hedging Instrument -21 -6 -250.0%

Balance Sheet

Balance Sheet
Metric FY 2026 FY 2025 YoY
Current Assets
Cash & Cash Equivalents 3,975 5,691 -30.2%
Receivables Net Current 27,985 25,643 +9.1%
Show Business Segments breakouts
North American Pharmaceutical · Investee 443 313 +41.5%
Inventory 24,207 23,001 +5.2%
Prepaid Expenses & Other Current Assets 1,043 1,063 -1.9%
Total Current Assets 57,210 55,398 +3.3%
Non-Current Assets
Property, Plant & Equipment 2,668 2,502 +6.6%
Operating Lease Right-of-Use Assets 2,058 1,782 +15.5%
Goodwill 11,316 10,022 +12.9%
Show Business Segments breakouts
Medical-Surgical Solutions · Operating Segments 2,507 2,507 0.0%
North American Pharmaceutical · Operating Segments 2,781 2,737 +1.6%
Oncology & Multispecialty · Operating Segments 3,963 2,724 +45.5%
Prescription Technology Solutions · Operating Segments 2,065 2,027 +1.9%
Intangible Assets 4,079 1,464 +178.6%
Show Finite Lived Intangible Assets By Major Class breakouts
Customer Relationships 760 825 -7.9%
Other Intangible Assets 95 4 +2275.0%
Provider networks 368 — —
Service Agreements 2,416 388 +522.7%
Technology Based Intangible Assets 157 147 +6.8%
Trademarks And Trade Names 283 100 +183.0%
Other Non-Current Assets 4,992 3,972 +25.7%
Total Assets 82,323 75,140 +9.6%
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 818 610 +34.1%
Deferred Tax Assets 432 367 +17.7%
Current Liabilities
Accounts Payable 59,973 55,330 +8.4%
Long Term Debt And Capital Lease Obligations Current 1,267 1,191 +6.4%
Operating Lease Liability Current 287 258 +11.2%
Accrued Liabilities 5,490 4,825 +13.8%
Total Current Liabilities 67,017 61,604 +8.8%
Non-Current Liabilities
Deferred Tax Liabilities 1,330 1,029 +29.3%
Operating Lease Liabilities 1,801 1,478 +21.9%
Litigation Reserve Noncurrent 5,091 5,601 -9.1%
Other Non-Current Liabilities 2,659 2,659 0.0%
Long-Term Debt 6,526 5,654 +15.4%
Show Fair Value Hierarchy breakouts
Fair Value Inputs Level2 6,526 5,654 +15.4%
Show Debt Instrument breakouts
1.30% Notes due August 15, 2026 · Loans Payable 500 499 +0.2%
1.63% Euro Notes due October 30, 2026 · Loans Payable 578 541 +6.8%
3.13% Sterling Notes due February 17, 2029 · Loans Payable 595 581 +2.4%
3.95% Notes due February 16, 2028 · Loans Payable 343 343 0.0%
4.25% Notes due September 15, 2029 · Loans Payable 500 500 0.0%
4.65% Notes due May 30, 2030 · Loans Payable 650 — —
4.75% Notes due May 30, 2029 · Loans Payable 196 196 0.0%
4.88% Notes due March 15, 2044 · Loans Payable 255 255 0.0%
4.90% Notes due July 15, 2028 · Loans Payable 400 399 +0.3%
4.95% Notes due May 30, 2032 · Loans Payable 650 — —
5.10% Notes due July 15, 2033 · Loans Payable 597 597 0.0%
5.25% Notes due May 30, 2035 · Loans Payable 699 — —
6.00% Notes due March 1, 2041 · Loans Payable 218 217 +0.5%
7.65% Debentures due March 1, 2027 · Loans Payable 150 150 0.0%
Show Long-Term Debt Type breakouts
Lease and other obligations 195 227 -14.1%
Total Liabilities (Q) — — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 287 47 +510.6%
Other Liabilities
Long Term Debt And Capital Lease Obligations 5,259 4,463 +17.8%
Redeemable Noncontrolling Interest Equity Common Carrying Amount 943 — —
Show Equity Components breakouts
Redeemable Noncontrolling Interests 943 — —
Stockholders' Equity
Common Stock 3 3 0.0%
Additional Paid-In Capital 8,284 8,373 -1.1%
Retained Earnings 22,291 17,921 +24.4%
Accumulated Other Comprehensive Income -745 -932 +20.1%
Treasury Stock Common Value -32,005 -27,439 -16.6%
Total Stockholders' Equity -2,172 -2,074 -4.7%
Minority Interest 395 380 +3.9%
Show Ownership breakouts
ClarusONE Sourcing Services, Vantage Oncology and SCRI Oncology 395 380 +3.9%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1,777 -1,694 -4.9%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment Net Gain Loss Including Portion Attributable To Noncontrolling Interest 16 14 +14.3%
Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest -708 -989 +28.4%
Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest 5 -4 +225.0%
Accumulated Other Comprehensive Income -745 -932 +20.1%
Additional Paid In Capital 8,284 8,373 -1.1%
Aoci Including Portion Attributable To Noncontrolling Interest -745 -932 +20.1%
Common Stock 3 3 0.0%
Noncontrolling Interest 395 380 +3.9%
Retained Earnings 22,291 17,921 +24.4%
Treasury Stock Common -32,005 -27,439 -16.6%
Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax -58 47 -223.4%
Total Liabilities & Equity 82,323 75,140 +9.6%

Cash Flow Statement

Cash Flow Statement
Metric FY 2026 FY 2025 YoY
Operating Activities
Depreciation 256 242 +5.8%
Adjustment For Amortization 473 394 +20.1%
Other Asset Impairment Charges 55 98 -43.9%
Increase Decrease In Deferred Income Taxes 230 -110 +309.1%
Inventory L I F O Reserve Period Charge -210 82 -356.1%
Operating Lease Expense 261 245 +6.5%
Gain Loss On Sale Of Other Assets -573 485 -218.1%
Provision For Doubtful Accounts 100 -130 +176.9%
Show Business Segments breakouts
North American Pharmaceutical · Operating Segments -210 — —
Other Non-Cash Items 302 424 -28.8%
Increase Decrease In Receivables -1,999 -3,935 +49.2%
Change in Inventory -1,082 -2,270 +52.3%
Change in Accounts Payable 4,317 8,301 -48.0%
Increase Decrease In Operating Lease Liability -270 -404 +33.2%
Increase Decrease In Accrued Taxes Payable -339 -136 -149.3%
Increase Decrease In Litigation Reserve -684 -401 -70.6%
Increase Decrease In Other Operating Capital Net 219 -281 +177.9%
Net Cash from Operations 6,155 6,085 +1.2%
Depreciation & Amortization 287 272 +5.5%
Deferred Income Taxes 230 -110 +309.1%
Investing Activities
Capital Expenditures -436 -537 +18.8%
Payments To Acquire Software -309 -322 +4.0%
Payments To Acquire Businesses Net Of Cash Acquired -3,416 -24 -14133.3%
Proceeds From Divestiture Of Businesses And Interests In Affiliates 830 179 +363.7%
Other Investing Activities -101 -29 -248.3%
Net Cash from Investing -3,432 -733 -368.2%
Financing Activities
Proceeds From Short Term Debt 9,247 15,086 -38.7%
Repayments Of Short Term Debt -9,247 -15,086 +38.7%
Proceeds From Issuance Of Long Term Debt 1,990 498 +299.6%
Repayments Of Long Term Debt -1,207 -519 -132.6%
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options 89 101 -11.9%
Share Repurchases -4,750 -3,146 -51.0%
Payments Of Dividends Common Stock -381 -345 -10.4%
Proceeds From Payments For Other Financing Activities -372 -554 +32.9%
Net Cash from Financing -4,631 -3,965 -16.8%
Supplemental
Restricted Cash Current -93 -265 +64.9%
Interest Paid 212 273 -22.3%
Income Taxes Paid 1,211 1,124 +7.7%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 20 -16 +225.0%
Net Change in Cash -1,888 1,371 -237.7%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 4,068 5,956 -31.7%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key